The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock

Toxins

Volumn 3, Issue 9, 2011, Pages 1185-1202

  Hicks, Caitlin W ^a,b   Cui, Xizhong ^b   Sweeney, Daniel A ^c   Li, Yan ^b   Barochia, Amisha ^b   Eichacker, Peter Q ^b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Washington Hospital   (United States)

Author keywords

Anthrax; Edema toxin; Lethal toxin; Myocardial function; Shock

Indexed keywords

ADEFOVIR; ANTHRAX IMMUNOGLOBULIN; ANTHRAX TOXIN; CYCLIC AMP; EDEMA TOXIN; EXOTOXIN; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LETHAL TOXIN; LIPOPOLYSACCHARIDE; RAXIBACUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL CELL WALL; CARDIOVASCULAR DISEASE; CENTRAL VENOUS PRESSURE; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; EXTRAVASATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOCONCENTRATION; HOST RESISTANCE; HUMAN; HYPONATREMIA; HYPOTENSION; INFLAMMATION; INTRAVENOUS DRUG ABUSE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PATHOGEN CLEARANCE; PATHOGENESIS; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SHOCK; SODIUM RETENTION; TACHYCARDIA; WATER RETENTION;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HUMANS; SHOCK;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 80053209619     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins3091185     Document Type: Review

References (86)

1. Jernigan, D.B.; Raghunathan, P.L.; Bell, B.P.; Brechner, R.; Bresnitz, E.A.; Butler, J.C.; Cetron, M.; Cohen, M.; Doyle, T.; Fischer, M.; et al. Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings. Emerg. Infect. Dis. 2002, 8, 1019-1028.
2. Ramsay, C.N.; Stirling, A.; Smith, J.; Hawkins, G.; Brooks, T.; Hood, J.; Penrice, G.; Browning, L.M.; Ahmed, S. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro. Surveill. 2010, 15, 2.
3. Ringertz, S.H.; Hoiby, E.A.; Jensenius, M.; Maehlen, J.; Caugant, D.A.; Myklebust, A.; Fossum, K. Injectional anthrax in a heroin skin-popper. Lancet 2000, 356, 1574-1575.
4. Winters, B.D.; Eberlein, M.; Leung, J.; Needham, D.M.; Pronovost, P.J.; Sevransky, J.E. Long-term mortality and quality of life in sepsis: A systematic review. Crit. Care Med. 2010, 38, 1276-1283.
5. Booth, M.G.; Hood, J.; Brooks, T.J.; Hart, A. Anthrax infection in drug users. Lancet 2010, 375, 1345-1346.
6. Bradley, K.A.; Mogridge, J.; Mourez, M.; Collier, R.J.; Young, J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414, 225-229.
7. Scobie, H.M.; Rainey, G.J.; Bradley, K.A.; Young, J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 5170-5174.
8. Sherer, K.; Li, Y.; Cui, X.; Eichacker, P.Q. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: Implications for therapy. Am. J. Respir. Crit. Care Med. 2007, 175, 211-221.
9. van der Goot, G.; Young, J.A. Receptors of anthrax toxin and cell entry. Mol. Aspects. Med. 2009, 30, 406-412.
10. Bell, S.E.; Mavila, A.; Salazar, R.; Bayless, K.J.; Kanagala, S.; Maxwell, S.A.; Davis, G.E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: Regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 2001, 114, 2755-2773.
11. Carson-Walter, E.B.; Watkins, D.N.; Nanda, A.; Vogelstein, B.; Kinzler, K.W.; St Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61, 6649-6655.
12. Cui, X.; Li, Y.; Li, X.; Laird, M.W.; Subramanian, M.; Moayeri, M.; Leppla, S.H.; Fitz, Y.; Su, J.; Sherer, K.; et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J. Infect. Dis. 2007, 195, 572-580.
13. Klimpel, K.R.; Molloy, S.S.; Thomas, G.; Leppla, S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 1992, 89, 10277-10281.
14. Milne, J.C.; Furlong, D.; Hanna, P.C.; Wall, J.S.; Collier, R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 1994, 269, 20607-20612.
15. Mogridge, J.; Cunningham, K.; Collier, R.J. Stoichiometry of anthrax toxin complexes. Biochemistry 2002, 41, 1079-1082.
16. Tonello, F.; Montecucco, C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol. Aspects. Med. 2009, 30, 431-438.
17. Leppla, S.H. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982, 79, 3162-3166.
18. Tang, W.J.; Guo, Q. The adenylyl cyclase activity of anthrax edema factor. Mol. Aspects. Med. 2009, 30, 423-430.
19. Tippetts, M.T.; Robertson, D.L. Molecular cloning and expression of the Bacillus anthracis edema factor toxin gene: A calmodulin-dependent adenylate cyclase. J. Bacteriol. 1988, 170, 2263-2266.
20. Moayeri, M.; Leppla, S.H. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects. Med. 2009, 30, 439-455.
21. Firoved, A.M.; Miller, G.F.; Moayeri, M.; Kakkar, R.; Shen, Y.; Wiggins, J.F.; McNally, E.M.; Tang, W.J.; Leppla, S.H. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 2005, 167, 1309-1320.
22. Hicks, C.W.; Li, Y.; Okugawa, S.; Solomon, S.B.; Moayeri, M.; Leppla, S.H.; Mohanty, A.; Subramanian, G.M.; Mignone, T.S.; Fitz, Y.; et al. Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H1108-H1118.
23. Sweeney, D.A.; Cui, X.; Solomon, S.B.; Vitberg, D.A.; Migone, T.S.; Scher, D.; Danner, R.L.; Natanson, C.; Subramanian, G.M.; Eichacker, P.Q. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J. Infect. Dis. 2010, 202, 1885-1896.
24. Smith, H.; Keppie, J.; Stanley, J.L.; Harris-Smith, P.W. The chemical basis of the virulence of Bacillus anthracis. IV. Secondary shock as the major factor in death of guinea-pigs from anthrax. Br. J. Exp. Pathol. 1955, 36, 323-335.
25. Stanley, J.L.; Smith, H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 1961, 26, 49-63.
26. Beall, F.A.; Dalldorf, F.G. The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. 1966, 116, 377-389.
27. Bonventre, P.F.; Eckert, N.J. Toxin production as a criterion for differentiating Bacillus cereus and Bacillus anthracis. J. Bacteriol. 1963, 85, 490-491.
28. Fish, D.C.; Lincoln, R.E. In vivo-produced anthrax toxin. J. Bacteriol. 1968, 95, 919-924.
29. Vick, J.A.; Lincoln, R.E.; Klein, F.; Mahlandt, B.G.; Walker, J.S.; Fish, D.C. Neurological and physiological responses of the primate to anthrax toxin. J. Infect. Dis. 1968, 118, 85-96.
30. Moayeri, M.; Haines, D.; Young, H.A.; Leppla, S.H. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 2003, 112, 670-682.
31. Cui, X.; Moayeri, M.; Li, Y.; Li, X.; Haley, M.; Fitz, Y.; Correa-Araujo, R.; Banks, S.M.; Leppla, S.H.; Eichacker, P.Q. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286, R699-R709.
32. Gozes, Y.; Moayeri, M.; Wiggins, J.F.; Leppla, S.H. Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect. Immun. 2006, 74, 1266-1272.
33. Kirby, J.E. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 2004, 72, 430-439.
34. Rolando, M.; Munro, P.; Stefani, C.; Auberger, P.; Flatau, G.; Lemichez, E. Injection of Staphylococcus aureus EDIN by the Bacillus anthracis protective antigen machinery induces vascular permeability. Infect. Immun. 2009, 77, 3596-3601.
35. Warfel, J.M.; Steele, A.D.; D'Agnillo, F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 2005, 166, 1871-1881.
36. Guichard, A.; McGillivray, S.M.; Cruz-Moreno, B.; van Sorge, N.M.; Nizet, V.; Bier, E. Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature 2010, 467, 854-858.
37. Bolcome, R.E., III; Chan, J. Constitutive MEK1 activation rescues anthrax lethal toxin-induced vascular effects in vivo. Infect. Immun. 2010, 78, 5043-5053.
38. Bolcome, R.E., III; Sullivan, S.E.; Zeller, R.; Barker, A.P.; Collier, R.J.; Chan, J. Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature. Proc. Natl. Acad. Sci. USA 2008, 105, 2439-2444.
39. Watson, L.E.; Kuo, S.R.; Katki, K.; Dang, T.; Park, S.K.; Dostal, D.E.; Tang, W.J.; Leppla, S.H.; Frankel, A.E. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 2007, 2, doi:10.1371/journal.pone.0000466.
40. Watson, L.E.; Mock, J.; Lal, H.; Lu, G.; Bourdeau, R.W.; Tang, W.J.; Leppla, S.H.; Dostal, D.E.; Frankel, A.E. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front. Biosci. 2007, 12, 4670-4675.
41. Golden, H.B.; Watson, L.E.; Lal, H.; Verma, S.K.; Foster, D.M.; Kuo, S.R.; Sharma, A.; Frankel, A.; Dostal, D.E. Anthrax toxin: Pathologic effects on the cardiovascular system. Front. Biosci. 2009, 14, 2335-2357.
42. Moayeri, M.; Crown, D.; Dorward, D.W.; Gardner, D.; Ward, J.M.; Li, Y.; Cui, X.; Eichacker, P.; Leppla, S.H. The heart is an early target of anthrax lethal toxin in mice: A protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog. 2009, 5, doi:10.1371/journal.ppat.1000456.
43. Lips, D.J.; Bueno, O.F.; Wilkins, B.J.; Purcell, N.H.; Kaiser, R.A.; Lorenz, J.N.; Voisin, L.; Saba-El-Leil, M.K.; Meloche, S.; et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 2004, 109, 1938-1941.
44. Purcell, N.H.; Wilkins, B.J.; York, A.; Saba-El-Leil, M.K.; Meloche, S.; Robbins, J.; Molkentin, J.D. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 2007, 104, 14074-14079.
45. Yamaguchi, O.; Watanabe, T.; Nishida, K.; Kashiwase, K.; Higuchi, Y.; Takeda, T.; Hikoso, S.; Hirotani, S.; Asahi, M.; Taniike, M.; et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 2004, 114, 937-943.
46. 2+ handling via a NADPH oxidase-dependent mechanism. PLoS One 2010, 5, e13335.
47. Cui, X.; Li, Y.; Li, X.; Haley, M.; Moayeri, M.; Fitz, Y.; Leppla, S.H.; Eichacker, P.Q. Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis. 2006, 193, 829-840.
48. Hanna, P.C.; Acosta, D.; Collier, R.J. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 1993, 90, 10198-10201.
49. Tournier, J.N.; Rossi Paccani, S.; Quesnel-Hellmann, A.; Baldari, C.T. Anthrax toxins: A weapon to systematically dismantle the host immune defenses. Mol. Aspects. Med. 2009, 30, 456-466.
50. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 1991, 59, 3472-3477.
51. Molin, F.D.; Fasanella, A.; Simonato, M.; Garofolo, G.; Montecucco, C.; Tonello, F. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 2008, 52, 824-828.
52. Quinn, C.P.; Shone, C.C.; Turnbull, P.C.; Melling, J. Purification of anthrax-toxin components by high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography. Biochem. J. 1988, 252, 753-758.
53. Cooksey, B.A.; Sampey, G.C.; Pierre, J.L.; Zhang, X.; Karwoski, J.D.; Choi, G.H.; Laird, M.W. Production of biologically active Bacillus anthracis edema factor in Escherichia coli. Biotechnol. Prog. 2004, 20, 1651-1659.
54. Jernigan, J.A.; Stephens, D.S.; Ashford, D.A.; Omenaca, C.; Topiel, M.S.; Galbraith, M.; Tapper, M.; Fisk, T.L.; Zaki, S.; Popovic, T.; et al. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 2001, 7, 933-944.
55. Griffith, T.M.; Taylor, H.J. Cyclic AMP mediates EDHF-type relaxations of rabbit jugular vein. Biochem. Biophys. Res. Commun. 1999, 263, 52-57.
56. Stehlik, J.; Movsesian, M.A. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert. Opin. Investig. Drugs 2006, 15, 733-742.
57. Borer, J.S. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat. Clin. Pract. Cardiovasc. Med. 2004, 1, 103-109.
58. Katz, A.M. Physilogy of the Heart, 3rd ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; pp. 255-286.
59. Shen, Y.; Zhukovskaya, N.L.; Zimmer, M.I.; Soelaiman, S.; Bergson, P.; Wang, C.R.; Gibbs, C.S.; Tang, W.J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004, 101, 3242-3247.
60. Friedler, R.M.; Kurokawa, K.; Coburn, J.W.; Massry, S.G. Renal action of cholera toxin: I. Effects on urinary excretion of electrolytes and cyclic AMP. Kidney Int. 1975, 7, 77-85.
61. Kurokawa, K.; Friedler, R.M.; Massry, S.G. Renal action of cholera toxin: II. Effects on adenylate cyclase-cyclic AMP system. Kidney Int. 1975, 7, 137-144.
62. Pierce, N.F.; Graybill, J.R.; Kaplan, M.M.; Bouwman, D.L. Systemic effects of parenteral cholera enterotoxin in dogs. J. Lab. Clin. Med. 1972, 79, 145-156.
63. Kuehnert, M.J.; Doyle, T.J.; Hill, H.A.; Bridges, C.B.; Jernigan, J.A.; Dull, P.M.; Reissman, D.B.; Ashford, D.A.; Jernigan, D.B. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin. Infect. Dis. 2003, 36, 328-336.
64. Firoved, A.M.; Moayeri, M.; Wiggins, J.F.; Shen, Y.; Tang, W.J.; Leppla, S.H. Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin. Infect. Immun. 2007, 75, 2120-2125.
65. Maldonado-Arocho, F.J.; Fulcher, J.A.; Lee, B.; Bradley, K.A. Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Mol. Microbiol. 2006, 61, 324-337.
66. Paccani, S.R.; Tonello, F.; Ghittoni, R.; Natale, M.; Muraro, L.; D'Elios, M.M.; Tang, W.J.; Montecucco, C.; Baldari, C.T. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005, 201, 325-331.
67. Tournier, J.N.; Quesnel-Hellmann, A.; Mathieu, J.; Montecucco, C.; Tang, W.J.; Mock, M.; Vidal, D.R.; Goossens, P.L. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 2005, 174, 4934-4941.
68. Chakrabarty, K.; Wu, W.; Booth, J.L.; Duggan, E.S.; Nagle, N.N.; Coggeshall, K.M.; Metcalf, J.P. Human lung innate immune response to Bacillus anthracis spore infection. Infect. Immun. 2007, 75, 3729-3738.
69. Heninger, S.; Drysdale, M.; Lovchik, J.; Hutt, J.; Lipscomb, M.F.; Koehler, T.M.; Lyons, C.R. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 2006, 74, 6067-6074.
70. Pickering, A.K.; Osorio, M.; Lee, G.M.; Grippe, V.K.; Bray, M.; Merkel, T.J. Cytokine response to infection with Bacillus anthracis spores. Infect. Immun. 2004, 72, 6382-6389.
71. Stearns-Kurosawa, D.J.; Lupu, F.; Taylor, F.B., Jr.; Kinasewitz, G.; Kurosawa, S. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am. J. Pathol. 2006, 169, 433-444.
72. Popov, S.G.; Villasmil, R.; Bernardi, J.; Grene, E.; Cardwell, J.; Popova, T.; Wu, A.; Alibek, D.; Bailey, C.; Alibek, K. Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett. 2002, 527, 211-215.
73. Triantafilou, M.; Uddin, A.; Maher, S.; Charalambous, N.; Hamm, T.S.; Alsumaiti, A.; Triantafilou, K. Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers. Cell Microbiol. 2007, 9, 2880-2892.
74. Hsu, L.C.; Ali, S.R.; McGillivray, S.; Tseng, P.H.; Mariathasan, S.; Humke, E.W.; Eckmann, L.; Powell, J.J.; Nizet, V.; Dixit, V.M.; et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. USA 2008, 105, 7803-7808.
75. Cui, X.; Su, J.; Li, Y.; Shiloach, J.; Solomon, S.; Kaufman, J.B.; Mani, H.; Fitz, Y.; Weng, J.; Altaweel, L.; et al. Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensiv. Care Med. 2010, 36, 148-156.
76. Iyer, J.K.; Khurana, T.; Langer, M.; West, C.M.; Ballard, J.D.; Metcalf, J.P.; Merkel, T.J.; Coggeshall, K.M. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect. Immun. 2010, 78, 2418-2428.
77. Langer, M.; Malykhin, A.; Maeda, K.; Chakrabarty, K.; Williamson, K.S.; Feasley, C.L.; West, C.M.; Metcalf, J.P.; Coggeshall, K.M. Bacillus anthracis peptidoglycan stimulates an inflammatory response in monocytes through the p38 mitogen-activated protein kinase pathway. PLoS One 2008, 3, e3706.
78. Popov, S.G.; Popova, T.G.; Hopkins, S.; Weinstein, R.S.; MacAfee, R.; Fryxell, K.J.; Chandhoke, V.; Bailey, C.; Alibek, K. Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect. Dis. 2005, 5, doi:10.1186/1471-2334-5-25.
79. Adekoya, O.A.; Sylte, I. The thermolysin family (M4) of enzymes: Therapeutic and biotechnological potential. Chem. Biol. Drug Des. 2009, 73, 7-16.
80. Fisher, J.F.; Mobashery, S. Mechanism-based profiling of MMPs. Methods Mol. Biol. 2010, 622, 471-487.
81. Holty, J.E.; Bravata, D.M.; Liu, H.; Olshen, R.A.; McDonald, K.M.; Owens, D.K. Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. 2006, 144, 270-280.
82. Migone, T.S.; Subramanian, G.M.; Zhong, J.; Healey, L.M.; Corey, A.; Devalaraja, M.; Lo, L.; Ullrich, S.; Zimmerman, J.; Chen, A.; et al. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 2009, 361, 135-144.
83. Centers for Disease Control and Prevention. E-IND Protocol: One Time Emergency Use of Liquid 5% Anthrax Immune Globulin for Treatment of Severe Anthrax.
84. Walsh, J.J.; Pesik, N.; Quinn, C.P.; Urdaneta, V.; Dykewicz, C.A.; Boyer, A.E.; Guarner, J.; Wilkins, P.; Norville, K.J.; Barr, J.R.; et al. A case of naturally acquired inhalation anthrax: Clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 2007, 44, 968-971.
85. Subramanian, G.M.; Cronin, P.W.; Poley, G.; Weinstein, A.; Stoughton, S.M.; Zhong, J.; Ou, Y.; Zmuda, J.F.; Osborn, B.L.; Freimuth, W.W. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. 2005, 41, 12-20.
86. Altaweel, L.; Chen, Z.; Moayeri, M.; Cui, X.; Li, Y.; Su, J.; Fitz, Y.; Johnson, S.; Leppla, S.H.; Purcell, R.; et al. Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. Crit. Care Med. 2011, 39, 1439-1447.